CORONA REMEDIES LIMITED Fair Value
CORONA · Healthcare · Current price ₹2,033.7
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹200 | 25% ROE fading to 12% over ~10 yrs, on ₹122 book |
| Relative P/E | ₹1,182 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹288 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹2,327 | Street consensus 12-month target price |
Is CORONA REMEDIES LIMITED undervalued?
DocStoX estimates the fair value of CORONA REMEDIES LIMITED at ₹820 per share, versus the current market price of ₹2,034. That puts the stock about -59.7% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹200), Relative P/E (₹1,182), Graham floor (₹288), Analyst target (₹2,327). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹200 (bear) to ₹820 (base) to ₹2,327 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on CORONA REMEDIES LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.